Reply
Neil Mehta, Francis Y. Yao – 24 June 2020
Comparison of Clinical Outcomes of Induction Regimens in Patients Undergoing Liver Transplantation for Acute Liver Failure
Chimaobi M. Anugwom, Justin R. Parekh, Christine Hwang, Malcolm MacConmara, William M. Lee, Thomas M. Leventhal – 24 June 2020 – Spontaneous survival rates in acute liver failure (ALF) are vastly improved by liver transplantation (LT). However, the value of induction agents beyond steroids continues to be debated. To understand the potential benefit of different induction regimens in the ALF population, we compared overall survival of recipients undergoing LT in the United States for ALF.
Improvement in Quality of Life and Decrease in Large‐Volume Paracentesis Requirements With the Automated Low‐Flow Ascites Pump
Karan Kumar, Venugopal Bhaskaran Pillai – 24 June 2020
Letter to the Editor: Comment on Alpha‐Fetoprotein Decrease From >1,000 to <500 ng/mL in Patients With Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes
Sami Akbulut, Tevfik Tolga Sahin, Sezai Yilmaz – 24 June 2020
Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis
Fabian J. Bolte, Hartmut H.‐J. Schmidt, Bernhard Schlevogt – 24 June 2020
Unequal Effects of Myosin 5B Mutations in Liver and Intestine Determine the Clinical Presentation of Low‐Gamma‐Glutamyltransferase Cholestasis
Sven C.D. IJzendoorn, Qinghong Li, Yi‐ling Qiu, Jian‐She Wang, Arend W. Overeem – 24 June 2020
Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations for Management and Next Steps
Ariel Jaffe, Michael L. Schilsky, Ranjit Deshpande, Ramesh Batra – 23 June 2020 – The recent outbreak of the novel virus severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), which causes the corona virus disease of 2019 (COVID19), has spread globally and affects millions of people. This pandemic has taxed our health care system and disrupted normal operations, even life‐saving procedures, such as liver transplants. During these unprecedented times, providers and patients are imperiled and resources for diagnosis and care may be limited.
Pushing the Limits in Donation After Circulatory Death Donor Selection: Optimizing Graft Rehabilitation With Ex Vivo Machine Perfusion
Paolo Magistri, Tiziana Olivieri, Cristiano Guidetti, Gian Piero Guerrini, Vanni Agnoletti, Paolo Muiesan, Fabrizio Di Benedetto – 23 June 2020
Longterm Outcomes of Patients Undergoing Liver Transplantation for Acute‐on‐Chronic Liver Failure
Vinay Sundaram, Nadim Mahmud, Giovanni Perricone, Dev Katarey, Robert J. Wong, Constantine J. Karvellas, Brett E. Fortune, Robert S. Rahimi, Harapriya Maddur, Janice H. Jou, Michael Kriss, Lance L. Stein, Moses Lee, Rajiv Jalan, the Multi‐Organ Dysfunction, Evaluation for Liver Transplantation (MODEL) Consortium – 23 June 2020 – Recent data have demonstrated >80% 1‐year survival probability after liver transplantation (LT) for patients with severe acute‐on‐chronic liver failure (ACLF). However, longterm outcomes and complications are still unknown for this population.
Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation
Pratima Sharma, Kevin Moore, Daniel Ganger, Priya Grewal, Robert S. Brown – 23 June 2020 – Hepatorenal syndrome (HRS) is one of the most ominous complications of portal hypertension in patients with decompensated cirrhosis and ascites. It is associated with very high mortality on the wait list. Liver transplantation (LT) is the most successful therapeutic option for patients with HRS.